HG

About This Project

Roughly 85% of small & medium sized hospitals remain without molecular diagnostics capabilities for human infectious diseases. Current solutions are expensive or have complex workflows and therefore have been unable to penetrate this large market segment. This is a key issue resulting in a more costly healthcare system and reducing efficiency when such testing must be carried out offsite rather than in-house. As accurate diagnostic results take longer to produce this can have a major negative impact on a patient’s health, particularly when urgent diagnosis and appropriate care may be required.

The in vitro HG diagnostics system, consisting of the portable testing device (HG Swift) as well as freeze dried reagents, is cost-effective and makes molecular diagnostics accessible to a laboratory or near patient environment such as an A&E or maternity labour ward with minimal training required. Furthermore the HG system is unique, producing highly accurate and rapid results (less than 60 minutes “sample to result”) and is flexible, capable of testing for multiple human infectious diseases. Once the HG solution has been commercialised, Hibergene can address the unmet needs of the large unmet market segment of small to medium sized hospitals by improving patient diagnosis and helping to create a more efficient healthcare system overall.

Topic
PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Year

2015

Cutoff

November

Beneficiaries

Coordinator

HiberGene Diagnostics

Country

Ireland